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Background. Among other mismatches between human and pig, incompatibilities in the blood coagulation systems
hamper the xenotransplantation of vascularized organs. The provision of the porcine endothelium with human
thrombomodulin (hTM) is hypothesized to overcome the impaired activation of protein C by a heterodimer con-
sisting of human thrombin and porcine TM.
Methods. We evaluated regulatory regions of the THBD gene, optimized vectors for transgene expression, and
generated hTM expressing pigs by somatic cell nuclear transfer. Genetically modified pigs were characterized at the
molecular, cellular, histological, and physiological levels.
Results. A 7.6-kb fragment containing the entire upstream region of the porcine THBD gene was found to drive a
high expression in a porcine endothelial cell line and was therefore used to control hTM expression in transgenic
pigs. The abundance of hTM was restricted to the endothelium, according to the predicted pattern, and the trans-
gene expression of hTM was stably inherited to the offspring. When endothelial cells from pigs carrying the hTM
transgeneVeither alone or in combination with an aGalTKO and a transgene encoding the human CD46Vwere
tested in a coagulation assay with human whole blood, the clotting time was increased three- to four-fold (PG0.001)
compared to wild-type and aGalTKO/CD46 transgenic endothelial cells. This, for the first time, demonstrated the
anticoagulant properties of hTM on porcine endothelial cells in a human whole blood assay.
Conclusions. The biological efficacy of hTM suggests that the (multi-)transgenic donor pigs described here have the
potential to overcome coagulation incompatibilities in pig-to-primate xenotransplantation.
Keywords: Xenotransplantation, Coagulation incompatibility, Thrombomodulin, Transgenic donors, Human
thrombomodulin, Transgenic donor pigs.
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The use of multitransgenic donor pigs, as well as the ad-vanced preoperative and postoperative care of nonhuman
primates, has led to impressive progress in the xenotrans-
plantation of vascularized organs over the last decade, tempt-
ing one to think about its clinical implementation in the near
future (1). In particular, the survival of pig-to-baboon heart
transplants for up to 8 months inspires these ambitions (2).
Yet, such feats are still exceptional, and the immunosuppressive
regimens that have led to these promising data are far from
clinical application owing to the severe side effects that result
from systemic and high-dose administration of drugs. An
appealing approach to circumvent these complications would
be the genetic tailoring of donors because this allows the local
but sustained application of an active agent. In a recent article,
we demonstrated the applicability of such a strategy by using
islet transplants from transgenic pigs that sufficiently sup-
pressed T-cellYmediated rejection at the transplant site in
humanized mice but reduced the systemic burden of im-
munosuppression in the recipient by two orders of magni-
tude (3). Similarly, the coagulation problems that occur in
xenotransplantation of vascularized organs (4, 5) might be
resolved by using genetically modified donors. Coagulation
issues in xenografts have been supposed to occur due to in-
compatibilities between human blood and the porcine vessel
wall, with the main obstacle being the impaired activation
of protein C by a heterodimer consisting of human throm-
bin and porcine thrombomodulin (6). Numerous attempts
to overcome this problem have been suggested (reviewed in
Cowan et al. (7)), but the most convincing approach would,
in any case, be the transgenic expression of the human
variant of thrombomodulin (hTM) in donor pigs, in par-
ticular as the molecule not only has anticoagulant but also
anti-inflammatory properties (8). The beneficial effect of
hTM has been demonstrated in early xenoperfusion studies
(9, 10), and two models of hTM expressing pigs have been
presented recently (11, 12). In contrast to these studies that
used ubiquitously active promoters to drive hTM expres-
sion, other studies aimed at the identification of regulatory
elements to restrict the abundance of a transgene to the en-
dothelial wall (13Y15) as the correct balance of the blood
coagulation system might require not only the presence of
functionally compatible key players but also their tightly
controlled expression (16, 17). The multifaceted regulation
of thrombomodulin on the transcriptional as well as post-
translational level seems to involve numerous stimulators
such as shear stress, hypoxia, reactive oxygen species, free
fatty acids, or inflammation (reviewed in Conway (8)) and
suggests a THBD promoter to control hTM expression. Al-
though regulatory sequences from different species have been
successfully used in numerous transgenic mouse models,
species-specific transcriptional initiation has been described
in defined physiological processes such as the regulation of
pluripotency (18), embryo-maternal communication (19) or
immunology (20). Moreover, increasing evidence for a more
significant divergence in the transcriptional regulation even
between closely related species has been found (21, 22) and
the role of specific regulatory elements has been postula-
ted to be more relevant for expression control compared to
other parameters such as epigenetic pattern, cellular envi-
ronment, or the abundance of transcription factors (23).
Consequently, transgene expression in the pig might be
more efficiently initiated by porcine regulatory elements
than by orthologous sequences from human or mouse.
Thus, we (i) developed and tested an expression vector
for reliable transgene expression in porcine endothelial cells,
(ii) generated single- and multitransgenic pigs that exhibit
and inherit strong and endothelial-specific expression of
hTM, and (iii), for the first time, demonstrated the potential
of hTM on transgenic porcine endothelial cells to prolong
clotting time in a human whole-blood coagulation assay.
RESULTS
Interspecies Comparison of THBD
Regulatory Elements
As fundamental characteristics of promoter regions
should be conserved among related species, we examined
the thrombomodulin locus of human, macaque, mouse,
rat, dog, horse, cattle, dolphin, and pig to identify the most
essential regulatory elements (Fig. 1A; Figure S1, SDC,
http://links.lww.com/TP/A885). For the region between
the thrombomodulin encoding THBD gene and the up-
stream CD93 gene, multispecies alignments revealed huge
differences in the intergenic length, ranging from less than 7 kb
to almost 18 kb between the respective species. Nonetheless,
three regions were identified in the alignment, which showed
high homology between all species, whereas the fragments
in between were characterized by large gaps in one or more
sequences and a reduced similarity between the remaining
species. One region located closely to the 3¶-UTR of CD93
was predicted to contain another potential polyadenylation
site of the gene. At the very other end of the alignment, the
presumed core promoter of the THBD gene contained com-
monly conserved binding sites for numerous transcription
factors (TFs) and core promoter elements. The third region
8.5 kb upstream of the THBD transcription start might rep-
resent an enhancer element because it contained conserved
binding sites for diverse TFs as well. A fourth region 14.5 kb
upstream of the THBD transcription start is of particular in-
terest because eight species showed sequence homologies
similar to those in the other conserved regions as well as
potential TF binding sites, whereas this fragment was com-
pletely absent in the pig. Another interesting feature of the
porcine sequence was the unique presence of a potential insu-
lator segment adjacent to the novel potential polyadenylation
site of CD93.
Design of an Endothelial-Specific hTM
Expression Vector
Based on a genomic fragment containing the human
THBD locus, we introduced two modifications (Fig. 1B).
First, we replaced the 3¶-UTR and downstream region of
THBD by a widely used polyadenylation cassette from the
bovine growth hormone (GH) gene because the 3¶-UTR of
THBD has been described to cause mRNA instability in the
presence of cytokines (24). Second, we replaced the 5¶-UTR
and the upstream region of human THBD by a porcine frag-
ment containing the complete intergenic region between CD93
and THBD, the transcription start, as well as the 5¶-UTR. In
an in vitro assay, we transfected immortalized porcine en-
dothelial cells with the respective vectors, determined the
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proportion of hTM expressing cells by FACS analysis, and
clearly found the porcine promoter to drive a stronger ex-
pression than the human fragment (Fig. 1C; Figure S2,
SDC, http://links.lww.com/TP/A885).
Establishment of hTM Expressing Pigs
Primary fibroblasts from a wild-type pig and kidney
cells from an alpha1,3-galactosyl transferaseYdeficient (aGalTKO)
(25) and CD46 transgenic (26) pig were nucleofected with
FIGURE 1. Evaluation of THBD regulatory sequences. (A) From nine mammalian species, a 21-kb alignment of the
intergenic regions between the CD93 and THBD genes was generated. Four conserved regions (boxed) have been iden-
tified by a homology plot (upper panel), a density plot (middle panel, with white bars indicating gaps in the respective
species), as well as the accumulation of potential conserved TF binding sites (see SDC, http://links.lww.com/TP/A885).
The calculation of similarity matrices (lower panel) for these regions indicated strong evolutionary conservation among the
examined species with the exception of the j14.5-kb region that was lacking in pig but strongly conserved among the
other species. The shown homology values between pig and the other species for this region result from alignment arti-
facts. (B) Three different hTM constructs were compared. hTM0 consisted of a completely human genomic fragment; in
hTM1, the THBD 3¶-UTR and downstream region were replaced by a polyadenylation cassette from the bovine GH gene and
hTM2 contained the modified 3¶-end as well as the regulatory region upstream of the porcine THBD gene. (C) PEDSV.15
cells transfected with the constructs hTM0, hTM1, and hTM2 were stained with the anti-hTM antibody 6980-100 and ana-
lyzed by flow cytometry. Relative expression was determined by comparing the number of hTM-positive cells obtained with
each construct with background staining found in mock transfected PEDSV.15 cells (ctrl). Data represent mean values TSD
obtained in three independent experiments.
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FIGURE 2. Generation of hTM-transgenic pigs by SCNT. (A) The hTM2 construct was linked to a neomycin (neo) resistance
cassette for transfection into wild-type cells and to a blasticidin S (bsr) resistance cassette for transfection into aGalTKO/
CD46 cells. Localizations of the EcoRI restristion sites and the neo-specific probe for Southern blotting are indicated. (B)
Transgenic founders were examined for hTM expression by immunohistochemical detection of hTM (brown color) in vas-
cular endothelial cells in the cardiac tissue of hTM and aGalTKO/CD46/hTM founder pigs. Bars=20 Km. (C) Southern blot
examination of transgenic pigs carrying the hTM2-neo vector with the neo-specific probe on EcoRI-digested genomic
DNA. Marker is 1 kb ladder (Thermo Scientific); WT is wild-type control; 9742, 9744, 9780Y9782 are founder animals;
9943 was recloned from primary cells of founder 9781; and 1168Y1198 are transgenic offspring that were delivered from
two independent litters after mating 9943 to wild-type sows. The approximate sizes of the transgene-carrying fragments
are indicated on the right side. (D) The cloning and recloning efficiencies of SCNT experiments are within our long-
term experience.
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the hTM2 expression vector that has been linked to a neomy-
cin or a blasticidin S resistance cassette, respectively (Fig. 2A).
After growing cells under selection, stable cell clones were
pooled and used for somatic cell nuclear transfer (SCNT) to
generate hTM or aGalTKO/CD46/hTM pigs according to
Richter et al. (27). First, a total of eight hTM transgenic
founder pigs were generated and five were examined for
hTM expression in various organs either at the day of birth
or at the age of 1 month. All founders showed strong and
endothelial-specific expression of the transgene in heart and
kidney, and three of them showed additionally strong ex-
pression on vascular endothelial cells in the liver and lung.
Southern blot analysis suggested that the five founders rep-
resent four different integration patterns of the construct
(Fig. 2C). Primary kidney cells from an animal with a high
and endothelial-specific expression in the heart (Fig. 2B, left
panel) were chosen to reproduce the founder by SCNT. Two
delivered animals were raised to fertility, and one of them
was mated to wild-type sows. The inheritance of the trans-
gene integration pattern (Fig. 2C) and its expression pattern
to vital and fertile offspring over, as of now, two generations
indicates that the transgene does not interfere with animal
health or reproductive traits. Second, a total of three aGalTKO/
CD46/hTM founders were generated and examined for hTM
expression at an age of either a few days or 1 month. Cor-
responding to the findings for the hTM transgenic pigs, all
aGalTKO/CD46/hTM animals showed strong and endothelial-
specific hTM expression in the heart and kidney, and two
of them also revealed high hTM abundance on endothelial
cells of the lung and liver. A total of nine aGalTKO/CD46/
hTM animals have been reproduced by SCNT from primary
cells of a highly expressing founder with positive hTM im-
munoreactivity on vascular endothelial cells of cardiac tissue
specimens (Fig. 2B, right panel). The efficiencies of cloning
and recloning hTM-transgenic animals (Fig. 2D) reflect our
long-years’ experience (28).
For a more detailed analysis of transgene expression
and its biological function, individuals of both transgenic lines
were examined at the histological, cellular, molecular and
physiological levels. For both the hTM and the aGalTKO/
CD46/hTM lines, several animals were examined. As the results
were consistent within the lines, data from no. 1198 are shown
as representative for the hTM line and data from no. 1259 are
shown as representative for the aGalTKO/CD46/hTM line.
Expression Analysis of hTM
The expression of hTM in tissue specimens and cul-
tured endothelial cells was investigated using immunoche-
mical methods.
In cardiac tissue sections of both lines, hTM immu-
noreactivity was exclusively present on the endocardium
and in vessels of large as well as small caliber, displaying con-
gruent abundance patterns with the endothelial cell marker
von Willebrand factor (Fig. 3). In the kidney, hTM expres-
sion was present in the endothelia of intertubular capilla-
ries and larger vessels but was not detectable in glomerular
endothelia. The lungs of hTM and aGalTKO/CD46/hTM
pigs displayed diffuse endothelial hTM immunoreactivity,
whereas in the liver, endothelial hTM expression was de-
tected on the endothelia of large vessels but not on those of the
sinusoids (see Figure S3, SDC, http://links.lww.com/TP/A885).
The expression of the transgene on cultured aortic
endothelial cells was investigated in more detail with FACS,
immunofluorescence, and Western blot analyses. Immuno-
cytochemistry verified the endothelial nature of the culti-
vated cells by positive CD31 staining and showed broad
although unevenly distributed hTM expression (Fig. 4A).
The finding of prevalent hTM expression was confirmed in
flow cytometric analysis as at least 90% of the cells coexpressed
CD31 and hTM in both transgenic lines (Fig. 4B). The pres-
ence of different expression levels was verified at a more
quantitative level, as CD31-positive cells from aGalTKO/
CD46/hTM pigs revealed two clearly distinct populations
regarding the expression levels of hTM. In contrast, cells
from hTM pigs showed a more homogenous population
of cells that coexpressed CD31 and hTM. Cultivated endo-
thelial cells were also used to extract protein for Western blot
analysis. A single and distinct band corresponding to the
expected size of hTM (116 kDa) was detected with the hTM-
specific antibody (Fig. 4C).
Biological Function of hTM on Porcine
Endothelial Cells
In a first approach we tested whether hTM facilitated
the cleavage of protein C in the presence of human throm-
bin in a biochemical assay (Fig. 5A). We found clear evi-
dence that the amount of activated protein C (APC) in the
supernatant of hTM or aGalTKO/CD46/hTM cells increased
with the concentration of protein C in a dose-dependent man-
ner, whereas the turnover of protein C remained at the basal
level for any of the examined concentrations upon exposure
to control cells lacking hTM.
In a further experiment, we tested whether hTM also
possesses the ability to prevent blood coagulation/clotting
in a more physiologic assay that models the processes at the
interface of human blood and porcine vessel wall (29, 30).
Aortic endothelial cells from wild-type, hTM, aGalTKO/CD46,
and aGalTKO/CD46/hTM pigs were grown on microcarrier
beads and tested for their potential to prolong the clotting
time of freshly withdrawn, non-anticoagulated human
blood. While clotting time in the presence of aGalTKO/CD46
aortic endothelial cells was slightly but significantly pro-
longed (100.9T20.5 min, PG0.01) as compared to the wild-
type control (62.3T15.5 min), the effect of hTM either on
the wild-type background or in the triple-transgenic combi-
nation (aGalTKO/CD46/hTM) was more pronounced, re-
sulting in a three- to four-fold increase in clotting time
(176.1T13.5 min, PG0.001 for hTM and 190.8T14.0 min,
PG0.001 for aGalTKO/CD46/hTM) compared to wild-type
endothelial cells (Fig. 5B). As the increased coagulation time
in the presence of hTM-expressing cells might also result
from the cytoprotective properties of the transgene product,
we conducted another set of whole blood coagulation ex-
periments and took samples at distinct time points to eval-
uate the coverage of the beads with endothelial cells (see
Figure S4, SDC, http://links.lww.com/TP/A885). Albeit cells
being lost during the experiment, we did not observe differ-
ences between cells that express hTM and those that do not
and, thus, conclude that the main course of action of the hTM
transgene was by its control of thrombin regulation. The ef-
fective anticoagulatory properties of hTM were further illus-
trated by the formation of thrombinYantithrombin III
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(TAT) complexes (Fig. 5C). While wild-type and aGalTKO/
CD46 cells caused an immediate and steady increase of TATuntil
coagulation occurred, hTM transgenic cells kept TAT levels
constantly low in the first phase of the experiment. More-
over, although slightly increasing afterward, in these groups,
TAT did not reach the maximum levels that were seen in the
wild-type or aGalTKO/CD46 groups.
DISCUSSION
Advancements in the production of genetically mod-
ified donor pigs are a major reason for the progress that has
been made in xenotransplantation research in recent years.
Many different transgenic pigs have been described (31, 32)
and many more will be produced in the future. The biotech-
nological production process itself does not represent a main
hurdle any more, but the relatively long generation time of
the pig and economic aspects of housing are still challenging
factors. Thus, the detailed design of transgenic approaches
and their thorough evaluation is of importance for efficient
production of novel donor pig models. Consequently, we
made use of state-of-the-art in silico analysis tools to estimate
the potential of regulatory elements of the THBD gene and
compared different vector systems in vitro to determine the
most promising strategy for the generation of transgenic pigs
and, later on, put effort in comprehensive characterization at
the molecular, cellular, histological, and physiological levels.
Regarding the regulatory properties of THBD, the con-
served regions found in multispecies alignments are indicative
of common regulatory mechanisms of TM expression in
mammals, but the diverse length of the examined sequences
as well as the lack of certain segments in distinct species in
otherwise highly conserved regions might also indicate
unique properties in individual species. In the absence of
detailed promoter studies in the literature, the regulative
properties of THBD remain unclear, but the relatively short
intergenic region between THBD and the upstream CD93
in the pig allowed the usage of its entire length to control
transgene expression.
The fact that hTM is not expressed on all endothelial
cells and the distinct expression pattern of hTM in heart,
kidney, lung, and liver strictly mirrors the data that have
been published on a mouse model with a lacZ reporter
FIGURE 3. Immunohistochemical detection of hTM in the cardiac tissue of a wild-type control pig (WT), an hTM pig, a
GalTKO/CD46/hTM pig, and in human positive control tissue (PC). Sequential sections of left ventricular myocardia were
stained for the endothelial-specific von Willebrand factor (vWF) and hTM. In human and porcine cardiac tissue specimen,
vWF was restricted to endocardial and vascular endothelial cells (brown color, arrowheads, top row). Staining of hTM
corresponded to that of vWF in hTM and aGalKO/CD46/hTM pigs (brown color, arrows, second top row), whereas no
staining was seen in WT pigs. Positive hTM immunoreactivity (brown color) was also detected in the capillary endothelia in
the papillary muscle and in endocardial cells of the left atrioventricular heart valve of hTM and aGalTKO/CD46/hTM pigs
but not in WT pigs. Paraffin sections. Bars=20 Km.
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knockin in the murine Thbd locus (33), suggesting that TM
regulation is similar among mammalian species and fur-
ther indicating that the transgene expression resembles the
entire physiologic regulation of TM. This would be of relevance
as one might assume that species-specific incompatibilities
in blood coagulation have to be restored to a tightly regulated
FIGURE 4. Expression of hTM on endothelial cells from hTM and aGalTKO/CD46/hTM pigs. (A) Immunocytochemistry
showed hTM on paraformaldehyde-fixed endothelial cells from hTM and aGalTKO/CD46/hTM pigs, whereas hTM ex-
pression was absent on aGalTKO/CD46 cells. CD31 staining confirmed the endothelial origin of the cells. Bars=20 Km. (B)
FACS analysis revealed a strong coexpression of CD31 and hTM on hTM and aGalTKO/CD46/hTM endothelial cells. (C)
Immunoblot analysis showed a band with the correct size (116 kDa) demonstrating the expression of hTM in hTM and
aGalTKO/CD46/hTM endothelial cells but not in wild-type or aGalTKO/CD46 cells.
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physiological level, which is in contrast to other transgenic
donor pigs for xenotransplantation that aim at immuno-
logical rejection processes, where the functional properties
of a transgene may be less subject to transcriptional regu-
lation. Ongoing transplantation studies using aGalTKO/
CD46/hTM donors (B. Reichart and D. K. C. Cooper, personal
communication) will have to prove the relevance of our
strategy in nonhuman primate (NHP) models.
Albeit such transplantation experiments into primates
being the most stringent tool for the evaluation of geneti-
cally modified donor organs, they suffer from their tremen-
dous costs and the challenging experimental setup that is
attributed to the complexity of the NHP system. Thus,
the comprehensive examination of given transgenes under
constant regimens in vivo at experimental numbers that
are sufficient for scientific conclusions is limited to a small
FIGURE 5. Biological function of the hTM transgene. (A) The ability of porcine endothelial cells to activate protein C in the
presence of human thrombin was evaluated in a biochemical assay. The abundance of APC was detected colorimetrically.
hTM transgenic endothelial cells revealed clear and concentration-dependent APCproduction when the amount of protein C
was increased, whereas control cells (aGalTKO and WT) did not show any protein C turnover. Data are plotted as mean
values, and standard deviations are indicated when they were above 0.025 OD405. The inset shows the significance of area
under the curve differences between the groups. Four independent experiments were performed for each group. Signif-
icance test was performed using one-way analysis of variance with Bonferroni correction. (B) Measurement of the clotting
time after incubation of freshly withdrawn, non-anticoagulated whole human blood with wild-type or genetically modified
endothelial cells cultivated on microcarrier beads. Microcarriers with or without collagen coating, incubated with blood,
showed a strong procoagulant property with a short clotting time. Microcarriers covered by confluent hTM or aGalTKO/
CD46/hTM endothelial cells showed a strong anticoagulant effect compared to wild-type and aGalTKO/CD46 PAECs. Four
independent experiments were performed for each group. Significance test was performed using one-way analysis of
variance with Bonferroni correction. (C) Formation of thrombinYantithrombin III (TAT) complexes was determined as a fluid
phase coagulation parameter (thrombin generation) in EDTA plasma samples taken from whole blood coagulation assays at
regular time intervals of 30 min until coagulation occurred (indicated by ‘‘†’’). TAT is indicated as mean value (T standard
deviation when it was 910.0 ng/mL). Three independent experiments were performed for each group.
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number of transgenic combinations, and thus, they have to
be selected by preevaluation in less complex systems. Here,
we used an in vitro assay that exploits the natural antico-
agulant properties of endothelial cells in combination with
whole, non-anticoagulated human blood to test the effi-
cacy of the hTM transgene product in coagulation control,
either alone or in combination with the aGalTKO/CD46
transgenic background. Our coagulation assay confirmed
the beneficial effect of hTM either on the wild-type or on
the aGalTKO/CD46 background. These findings illustrate the
suitability of the whole blood coagulation assay for the eval-
uation of clotting mechanisms in xenotransplantation ap-
proaches because it facilitates the analysis of several transgene
combinations and, moreover, resembles the immediate in-
teraction of porcine endothelium and human blood, also
potentially avoiding wrong conclusions from in vivo trans-
plantation models due to differences in the coagulation sys-
tems between NHP and man (34).
In summary, we developed a novel genetically modi-
fied pig for xenotransplantation and present evidence for its
potential to overcome the incompatibilities in the coagula-
tion systems between pig and man.
MATERIALS AND METHODS
Pig Housing
Animal experiments have been carried out according to the guidelines
of the responsible authority (Regierung von Oberbayern, approval no.
55.2-1-54-2531-54).
Bioinformatic Analysis
Sequences were fetched from the Ensembl genome browser (www.ensembl.org)
and prepared in BioEdit (35). Mobile genetic elements were removed by
RepeatMasker (36), and multiple alignments were done by ClustalW2 (37)
and by using the Genomatix ElDorado/Gene2Promoter and GEMS Launcher
software packages (Genomatix, Munich, Germany). The latter was also used
to assign binding sites of common transcription factors.
Vector Construction
Genomic fragments of the human and porcine THBD genes were excised
from the BACs RP4-753D10 and CH242-263H13, respectively. The frag-
ments were combined with other genetic elements using a two-step poly-
merase chain reaction, Cre-mediated recombination, and other conventional
cloning procedures.
Vector Evaluation
The immortalized porcine endothelial cell line PEDSV.15 (kindly pro-
vided by Prof. J. Seebach, Geneva (38)) was used for transfection and ana-
lyzed for hTM expression by flow cytometry.
Founder Pig Generation
Transgenic pigs were established according to Richter et al. (27) and
Klymiuk et al. (39) using the hTM2 expression vector and raised up to an
age of 2.5 months. Genotyping was carried out as described elsewhere (40).
Founders with a high-level expression of hTM were reestablished by SCNT
and raised for breeding purposes.
Necropsy, Histopathology, and
Immunohistochemistry
For histological examination, cardiac tissue samples (including left and
right heart ventricles, papillary muscles, and heart valves) and specimens of
liver, kidney, and lung were taken from hTM-transgenic pigs and aGalTKO/
CD46/hTM pigs. Control tissues were obtained from age-matched male
wild-type pigs.
Expression Analysis of Aortic Endothelial Cells
Porcine aortic endothelial cells (PAECs) were isolated from the aorta
of transgenic pigs as described earlier (38) with minor modifications. Co-
localization studies of hTM were performed with the endothelial-specific
marker PECAM-1 (CD31). Cultivated cells were then analyzed either in
a multicolor flow cytometric assay, immunocytochemistry, or Western
blot analysis.
APC Assay
The measurement of APC was performed with confluent PAECs on a
96-well plate.
Coagulation Assay
The coagulation-inhibiting effects of the different genetically modified
porcine endothelial cells were monitored in vitro using PAECs grown on
microcarrier beads and whole, non-anticoagulated human blood as previ-
ously described (29, 30). Details about endothelial cell culture on micro-
carriers and the coagulation assay are described in the Supplemental
Material. (see SDC, http://links.lww.com/TP/A885). Human blood was drawn
from healthy volunteers.
For further details on materials and methods, see the Supplemental
Material (see SDC, http://links.lww.com/TP/A885).
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